At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 392 enrolled
Drug / intervention
SPARC0921 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of SPARC0921 in Subjects With Spasticity
Sun Pharma Advanced Research Company Limited·interventional·Posted Oct 21, 2011·Updated Jun 18, 2019
In Brief
A Phase 3 clinical trial evaluating SPARC0921 and Placebo0921 for Spasticity. Completed, enrolled 392 participants across 73 sites in 5 countries.
Detailed Summary
The purpose of this study is to assess whether SPARC0921 demonstrate efficacy and safety in the treatment of spasticity.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSpasticity
CountriesGermany, Hungary, Russia, Ukraine, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedOct 2011
Enrollment StartNov 2012
Primary CompletionAug 2017
TodayJul 2026
First PostedOct 21, 2011
Enrollment StartNov 14, 2012
Primary CompletionAug 25, 2017
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 14.7 years ago
Interventions
SPARC0921drug
Placebo0921drug